entertainment -WSS

entertainment

author：knowledge 2025-09-30 23:19:33 - browse：345

Daphne Koller -- biotech coverage from STAT — Daphne Koller, early biotech AI entrant Insitro's founder, CEO and board member. Courtesy Jerrick Mitra/Insitro

New artificial intelligence technologies made headlines last year for their ability to do everything from generating fake musical duets to understanding how proteins fold. But in biotech, one of the most well-funded AI players has been quiet.

Insitro, a South San Francisco firm, was founded in 2018 by Daphne Koller, who had previously been a Stanford professor, a 2004 MacArthur “genius” grant recipient, and the co-founder and co-CEO of the online course company Coursera. It raised more than $643 million in venture capital, according to PitchBook, from investors including T. Rowe Price, ARCH Venture Partners, and Casdin Capital. The company now has more than 260 employees spread out over 107,000 square feet of laboratory and office space.

But what exactly is Koller building?

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Argenx drug significantly slows progression of nerve disorder

knowledge

hotspot

WSS

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

How to bring more disabled researchers into academia

Care demand spikes challenge UnitedHealth’s provider arm

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Why police arrested suspected Gilgo Beach killer away from his house

hotspot

entertainment

Wikipedia

Bright Health sells Medicare Advantage business to Molina

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Drug repurposing or repositioning? The language matters

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Novavax promises a turnaround & Lilly roils the obesity market

J&J expands global access to TB drug amid advocacy campaign

Guidelines to prevent youth baseball injuries need more muscle

Precocious puberty in girls comes with mental health risks

The high cost of giving birth even with insurance

First medicine developed to treat MASH expected to be approved soon

hotspot

Amylyx ALS drug fails large clinical trial

Argenx drug significantly slows progression of nerve disorder

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Who gets to use the title 'doctor'?

UnitedHealth quietly bought dozens of outpatient centers

The Readout: Amylyx, Alumis, and Lundbeck drug updates

knowledge

knowledge

hotspot

hotspot